Literature DB >> 9115639

Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor.

Y Daaka1, W Zhu, H Friedman, T W Klein.   

Abstract

Previously, we reported that the cannabinoid delta9-tetrahydrocannabinol (THC) increased the expression of interleukin-2 (IL-2) receptor (R) alpha and beta proteins and mRNAs in NKB61A2 cells, but decreased the level of the gamma-chain message. The drug increased beta-chain message stability rather than increased transcription. In the present study, we examined the mechanism responsible for the drug-induced increase in alpha-chain message in NKB61A2 cells. Nuclear run-on and mRNA stability studies showed THC increased the level of alpha gene transcription but had no effect on mRNA stability. Because expression of this gene is regulated by nuclear factor (NF)-kappaB, we next tested the drug effect on the nuclear level of this protein using the electromobility shift assay. These studies showed a drug-induced increase in NF-kappaB activity. To link the increased nuclear factor activity with the THC-induced increase in IL-2R alpha message, antisense oligodeoxynucleotides were used to inhibit expression of the RelA component of NF-kappaB. These results showed anti-RelA antisense eliminated the cannabinoid-induced upregulation of both alpha mRNA and RelA protein. Furthermore, inhibition of the cannabinoid receptor type 1 with antisense oligomers also eliminated the drug effect on the alpha message. These results suggest that THC treatment of NKB61A2 cells increases IL-2R alpha gene transcription by increasing the nuclear level of NF-kappaB through a mechanism involving cannabinoid receptor type 1 expression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9115639     DOI: 10.1089/dna.1997.16.301

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  9 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Dietary lecithin source affects growth potential and gene expression in Sparus aurata larvae.

Authors:  Dulce Alves Martins; Alicia Estévez; Neil C Stickland; Bigboy H Simbi; Manuel Yúfera
Journal:  Lipids       Date:  2010-09-10       Impact factor: 1.880

3.  CB(1) and CB(2) cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection.

Authors:  Catherine A Newton; Ping-Jen Chou; Izabella Perkins; Thomas W Klein
Journal:  J Neuroimmune Pharmacol       Date:  2008-09-16       Impact factor: 4.147

4.  The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development.

Authors:  Duo Zheng; Ann M Bode; Qing Zhao; Yong-Yeon Cho; Feng Zhu; Wei-Ya Ma; Zigang Dong
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

5.  Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol.

Authors:  G C Chan; T R Hinds; S Impey; D R Storm
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

6.  Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors.

Authors:  Toby K Eisenstein; Joseph J Meissler; Qiana Wilson; John P Gaughan; Martin W Adler
Journal:  J Neuroimmunol       Date:  2007-07-19       Impact factor: 3.478

7.  Role of cannabinoids in the regulation of bone remodeling.

Authors:  Aymen I Idris; Stuart H Ralston
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-16       Impact factor: 5.555

Review 8.  Cannabinoid-induced immune suppression and modulation of antigen-presenting cells.

Authors:  Thomas W Klein; Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-03       Impact factor: 7.285

9.  Expression and functional relevance of cannabinoid receptor 1 in Hodgkin lymphoma.

Authors:  Alexander H Benz; Christoph Renné; Erik Maronde; Marco Koch; Urszula Grabiec; Sonja Kallendrusch; Benjamin Rengstl; Sebastian Newrzela; Sylvia Hartmann; Martin-Leo Hansmann; Faramarz Dehghani
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.